Good to see some buying coming in. Market definitely not pricing this correctly. Currently with an EV of $35m and minimum first year revenues of ~$6-8m, looks like a steal at these levels.
RBL Recce Pharmaceuticals advances global reach with Indonesia’s approval for Phase 3 Diabetic Foot Infection Trial